<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00726414</url>
  </required_header>
  <id_info>
    <org_study_id>R05-1613</org_study_id>
    <nct_id>NCT00726414</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg</brief_title>
  <official_title>A Relative Bioavailability Study of Quinine Sulfate Capsules 324mg Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mutual Pharmaceutical Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mutual Pharmaceutical Company, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate and compare the relative bioavailability of Quinine
      Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate and compare the relative bioavailability of Quinine
      Sulfate capsules following a single, oral dose in healthy volunteers under fasting and fed
      conditions.

      Twenty-two healthy, non-smoking, non-obese, male and female volunteers between the ages of 18
      and 45 years of age will be randomly assigned in a crossover fashion to receive each of two
      Quinine Sulfate dosing regimens in sequence with a 7 day washout period between dosing
      periods. On the morning of Day 1, subjects will receive either a single oral dose of Quinine
      Sulfate (2 x 324 mg capsules) following an overnight fast of at least 10 hours, or a single
      oral dose of Quinine Sulfate (2 x 324 mg capsules) 30 minutes after a standardized, high-fat
      breakfast. After a 7 day washout period, on the morning of Day 8, subjects will receive the
      alternate regimen. Blood samples will be drawn from all participants before dosing and for 48
      hours post-dose to adequately define the pharmacokinetics of Quinine Sulfate. A further goal
      of this study is to evaluate the safety and tolerability of this regimen in healthy
      volunteers. Subjects will be monitored throughout the confinement portion of the study for
      adverse reactions to the study drug and/or procedures. Blood pressure and heart rate will be
      measured prior to dosing and at 1, 2, 4 and 12 hours after each dose and at study exit. A 12
      lead electrocardiogram (EKG) will be recorded at study check-in and at 2, 4, 6, 12 and 24
      hours after dose administration. All adverse events whether elicited by query, spontaneously
      reported, or observed by clinic staff will be evaluated by the Investigator and reported in
      the subject's case report form.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) for Quinine Sulfate</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate</measure>
    <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine Sulfate 2 x 324 mg Capsules</intervention_name>
    <description>Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.</description>
    <arm_group_label>Quinine Sulfate Capsules 2 x 324 mg Capsules - Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quinine Sulfate 2 x 324 mg Capsules</intervention_name>
    <description>Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.</description>
    <arm_group_label>Quinine Sulfate Capsules 2 x 324 mg Capsules - Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening Demographics: All volunteers selected for this study will be healthy men and
             women 18 to 45 years of age at the time of dosing. Weight range will not exceed ±20%
             for height and body frame

          -  Screening Procedures: Each volunteer will complete the screening process within 28
             days prior to Period I dosing. Consent documents for both the screening evaluation and
             human immunodeficiency virus (HIV) antibody determination will be reviewed, discussed,
             and signed by each potential participant before full implementation of screening
             procedures

          -  Screening will include general observations, physical examination, demographics,
             medical history, an electrocardiogram, sitting blood pressure and heart rate,
             respiratory rate and temperature. The physical examination will include, but may not
             be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and
             central nervous systems

          -  Screening Procedures:

          -  Hematology: hematocrit, hemoglobin, white blood cell (WBC) count with differential,
             red blood cell (RBC) count, platelet count

          -  Clinical chemistry: serum creatinine, blood urea nitrogen (BUN), glucose, AST(SGOT -
             Serum glutamic-oxaloacetic transaminase), ALT(SGPT - Serum glutamic-pyruvic
             transaminase), albumin, total bilirubin, total protein, and alkaline phosphatase

          -  HIV antibody, hepatitis B surface antigen, hepatitis C antibody screens

          -  Urinalysis: by dipstick; full microscopic examination if dipstick positive; and

          -  Urine drug screen: ethyl alcohol, amphetamines, barbiturates, benzodiazepines,
             cannabinoids, cocaine metabolites, opiates and phencyclidine

          -  Serum pregnancy screen (female volunteers only)

          -  If female and:

          -  of childbearing potential, is practicing an acceptable method of birth control for the
             duration of the study as judged by the investigator(s), such as condom with
             spermicide, diaphragm with spermicide, intrauterine device (IUD), or abstinence; or

          -  is postmenopausal for at least 1 year; or

          -  is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy).

        Exclusion Criteria:

          -  Volunteers with a recent history of drug or alcohol addiction or abuse

          -  Volunteers with a presence of a clinically significant disorder involving the
             cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic,
             endocrine, or neurologic system(s) or psychiatric disease (as determined by clinical
             investigators)

          -  Volunteers whose clinical laboratory test values are outside the accepted reference
             range and when confirmed on re-examination are deemed to be clinically significant

          -  Volunteers demonstrating a reactive screen for hepatitis B surface antigen, hepatitis
             C antibody or HIV antibody

          -  Volunteers demonstrating a positive drug abuse screen when screened

          -  Female volunteers demonstrating a positive pregnancy screen

          -  Female volunteers who are currently breastfeeding

          -  Volunteers with a history of allergic response(s) to quinine or related drugs

          -  Volunteers with a history of clinically significant allergies including drug allergies

          -  Volunteers with a clinically significant illness during the last 4 weeks prior to
             Period I dosing (as determined by the clinical investigators)

          -  Volunteers who report donating greater than 150 mL of blood within 28 days prior to
             Period I dosing. All subjects will be advised not to donate blood for four weeks after
             completing the study

          -  Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to
             Period I dosing. All subjects will be advised not to donate plasma for four weeks
             after completing the study

          -  Volunteers who report receiving any investigational drug within 28 days prior to
             Period I dosing

          -  Volunteers who report taking any systemic prescription medication in the 14 days prior
             to Period I dosing

          -  Volunteers who currently use tobacco products

          -  Volunteers who have taken any drug known to induce or inhibit hepatic drug metabolism
             in the 28 days prior to Period I dosing

          -  Male volunteers with a corrected QT interval (QTc)&gt; 430 milliseconds (msec)on the
             screening electrocardiogram (ECG) or with clinically significant findings

          -  Female volunteers with a QTC&gt; 450 msec on the screening ECG or with clinically
             significant findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2008</study_first_posted>
  <results_first_submitted>December 4, 2009</results_first_submitted>
  <results_first_submitted_qc>January 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2010</results_first_posted>
  <last_update_submitted>January 13, 2010</last_update_submitted>
  <last_update_submitted_qc>January 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Matthew Davis, M.D.</name_title>
    <organization>Mutual Pharmaceutical Company, Inc.</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quinine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quinine Sulfate Under Fasted Then Fed Conditions</title>
          <description>On the morning of Day 1 subjects received one dose of Quinine Sulfate (2 x 324 mg capsules) after an overnight fast of at least 10 hours, followed by a 7 day washout period. On the morning of Day 8 subjects received one dose of Quinine Sulfate (2 x 324 mg capsules) 30 minutes following a standardized, high fat breakfast.</description>
        </group>
        <group group_id="P2">
          <title>Quinine Sulfate Under Fed Then Fasted Conditions</title>
          <description>On the morning of Day 1 subjects received one dose of Quinine Sulfate (2 x 324 mg capsules) 30 minutes following a standardized, high fat breakfast, followed by a 7 day washout period. On the morning of Day 8 subjects received one dose of Quinine Sulfate (2 x 324 mg capsules) following an overnight fast of at least 10 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period of 7 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quinine Sulfate Under Fed and Fasted Conditions</title>
          <description>All subjects received each of the two study regimens in a randomly assigned sequence of dosing periods. On the mornings of Day 1 and Day 8, each subject received one dose of Quinine Sulfate (2 x 324 mg capsules) following an overnight fast or 30 minutes following a standardized, high fat breakfast.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax) for Quinine Sulfate</title>
        <description>The maximum or peak concentration that Quinine Sulfate reaches in the plasma.</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
        <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Quinine Sulfate Under Fasted Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Quinine Sulfate Under Fed Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg 30 minutes following a standardized, high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) for Quinine Sulfate</title>
          <description>The maximum or peak concentration that Quinine Sulfate reaches in the plasma.</description>
          <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3,293.84" spread="750.85"/>
                    <measurement group_id="O2" value="3,424.30" spread="859.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate</title>
        <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
        <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Quinine Sulfate Under Fasted Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Quinine Sulfate Under Fed Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg 30 minutes following a standardized, high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)] for Quinine Sulfate</title>
          <description>The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable concentration (t), as calculated by the linear trapezoidal rule.</description>
          <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
          <units>ng-hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49,484.64" spread="15,831.86"/>
                    <measurement group_id="O2" value="51,228.07" spread="16,690.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>serial pharmacokinetic plasma concentrations were drawn prior to dose administration (0 hour) and at 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 16, 24, 36 and 48 hours after drug administration.</time_frame>
        <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Quinine Sulfate Under Fasted Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg after an overnight fast of at least 10 hours.</description>
          </group>
          <group group_id="O2">
            <title>Quinine Sulfate Under Fed Conditions</title>
            <description>Each subject received two capsules of Quinine Sulfate 324 mg 30 minutes following a standardized, high fat breakfast.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)] for Quinine Sulfate</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <population>Data from all 22 subjects enrolled in this study were used in the statistical analysis.</population>
          <units>ng-hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52,643.14" spread="18,056.00"/>
                    <measurement group_id="O2" value="54,409.12" spread="18,706.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quinine Sulfate Under Fasted Conditions</title>
          <description>Each subject received two capsules of Quinine Sulfate 324 mg after an overnight fast of at least 10 hours.</description>
        </group>
        <group group_id="E2">
          <title>Quinine Sulfate Under Fed Conditions</title>
          <description>Each subject received two capsules of Quinine Sulfate 324 mg 30 minutes following a standardized, high fat breakfast.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Mutual Phrmaceutical Company, Inc.</organization>
      <phone>215-697-1743</phone>
      <email>clinicaltrials@urlmutual.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

